New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism

References

• Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10–27.
   PubMedGoogle Scholar
• Kleeff J, Korc M, Apte M, et al. Plasma microRNA panels to diagnose pancreatic cancer: results from a multicenter study. Oncotarget. 2016;7:28000–28012.
   PubMedGoogle Scholar
• Paulson AS, Tran Cao HS, Tempero MA, et al. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013;144:1316–1326.
   PubMed Web of Science ®Google Scholar
• Guo S, Fesler A, Wang H, et al. microRNA based prognostic biomarkers in pancreatic cancer. Biomark Res. 2018;6:18.
   PubMed Web of Science ®Google Scholar
• Grasso C, Jansen G, Giovannetti E. Drug resistance in pancreatic cancer: impact of altered energy metabolism. Crit Rev Oncol Hematol. 2017;114:139–152.
   PubMed Web of Science ®Google Scholar
• Wu W, Zhao S. Metabolic changes in cancer: beyond the Warburg effect. Acta Biochim Biophys Sin (Shanghai). 2013;45(1):18–26.
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Serdjebi C, Peters GJ, et al. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016;78:1–12.
   PubMed Web of Science ®Google Scholar
• Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513–5518.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–3952.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966.
   PubMed Web of Science ®Google Scholar
• Santarpia M, Rolfo C, Peters GJ, et al. On the pharmacogenetics of non-small cell lung cancer treatment. Expert Opin Drug Metab Toxicol. 2016;12:307–317.
   PubMed Web of Science ®Google Scholar
• Propper D, Davidenko I, Bridgewater J, et al. Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. Ann Oncol. 2014;25:1384–1390.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Li CP, Nowara E, et al. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Br J Cancer. 2014;111:2067–2075.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Cucinotto I, Fiorillo L, Gualtieri S, et al. Nanoparticle albumin bound paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv. 2013;2013:1–10.
   Google Scholar
• Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317–1324.
   PubMed Web of Science ®Google Scholar
• Desai N. Drug delivery report winter. Technol Overviews. 2008:37–41.
   Google Scholar
• Neuzillet C, Tijeras-Raballand A, Cros J, et al. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev. 2013;32:585–602.
   Web of Science ®Google Scholar
• Hidalgo M, Plaza C, Musteanu M, et al. SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial. Clin Cancer Res. 2015;21:4811–4818.
   PubMed Web of Science ®Google Scholar
• Blomstrand H, Scheibling U, Bratthäll C, et al. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer. 2019;19:40.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer - a groupe tumeurs digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005;23:1228–1236.
   PubMed Web of Science ®Google Scholar
• James ES, Yao X, Cong X, et al. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). J Clin Oncol. 2014;32: 256–256.
   PubMedGoogle Scholar
• Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42:1311–1315.
   PubMed Web of Science ®Google Scholar
• Lowery MA, Yu KH, Adel NG, et al. Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol. 2012;30:4057.
   Google Scholar
• Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico nor. J Clin Oncol. 2007;25:1670–1676.
   PubMed Web of Science ®Google Scholar
• Vivaldi C, Caparello C, Musettini G, et al. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: patients’ outcome and analysis of prognostic factors. Int J Cancer. 2016;139:938–945.
   PubMed Web of Science ®Google Scholar
• Collisson EA, Olive KP. Pancreatic cancer: progress and challenges in a rapidly moving field. Cancer Res. 2017;77:1060–1062.
   PubMed Web of Science ®Google Scholar
• Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319–334.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Kleeff J, Michl P, et al. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15:333–348.
   PubMed Web of Science ®Google Scholar
• Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Futur Oncol. 2005;1:37–50.
   PubMedGoogle Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–866.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269.
   PubMed Web of Science ®Google Scholar
• Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. J Am Med Assoc. 2007;297:1901–1908.
   PubMed Web of Science ®Google Scholar
• Hwang JH, Voortman J, Giovannetti E, et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer Hoheisel J, editor. PLoS One. 2010;5:e10630.
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010;70:4528–4538.
   PubMed Web of Science ®Google Scholar
• Wei X, Wang W, Wang L, et al. MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4. Cancer Med. 2016;5:693–702.
   PubMed Web of Science ®Google Scholar
• Donahue TR, Nguyen AH, Moughan J, et al. Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer. J Surg Oncol. 2014;110:952–959.
   PubMed Web of Science ®Google Scholar
• Ohuchida K, Mizumoto K, Kayashima T, et al. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol. 2011;18:2381–2387.
   PubMed Web of Science ®Google Scholar
• Li J, Wu H, Li W, et al. Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. Oncogene. 2016;35:5501–5514.
   PubMed Web of Science ®Google Scholar
• Hiramoto H, Muramatsu T, Ichikawa D, et al. MiR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer. Sci Rep. 2017;7:4002.
   PubMed Web of Science ®Google Scholar
• Preis M, Gardner TB, Gordon SR, et al. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2011;17:5812–5821.
   PubMed Web of Science ®Google Scholar
• Giovannetti E, van der Velde A, Funel N, et al. High-Throughput MicroRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer Ellis NA, editor. PLoS One. 2012;7:e49145.
   PubMed Web of Science ®Google Scholar
• Maftouh M, Avan A, Funel N, et al. MiR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids. 2014;33:384–393.
   PubMed Web of Science ®Google Scholar
• Li Y, Vandenboom TG, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009;69:6704–6712.
   PubMed Web of Science ®Google Scholar
• Boni V, Bitarte N, Cristobal I, et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidylate synthase regulation. Mol Cancer Ther. 2010;9:2265–2275.
   PubMed Web of Science ®Google Scholar
• Cochrane DR, Spoelstra NS, Howe EN, et al. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther. 2009;8:1055–1066.
   PubMed Web of Science ®Google Scholar
• Yan HJ, Liu WS, Sun WH, et al. MiR-17-5p inhibitor enhances chemosensitivity to gemcitabine via upregulating Bim expression in pancreatic cancer cells. Dig Dis Sci. 2012;57:3160–3167.
   PubMed Web of Science ®Google Scholar
• Yu J, Ohuchida K, Mizumoto K, et al. MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis and involved in cancer cell proliferation and invasion. Cancer Biol Ther. 2010;10:748–757.
   PubMed Web of Science ®Google Scholar
• Meijer LL, Garajová I, Caparello C, et al. Plasma miR-181a-5p downregulation predicts response and improved survival after FOLFIRINOX in pancreatic ductal adenocarcinoma. Ann Surg. 2018;1.
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Warburg O. The metabolism of carcinoma cells 1. J Cancer Res. 1925;9:148–163.
   Google Scholar
• Heiden Vander MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–1033.
   PubMed Web of Science ®Google Scholar
• Weber GF. Time and circumstances: cancer cell metabolism at various stages of disease progression. Front Oncol. 2016;6:257.
   PubMed Web of Science ®Google Scholar
• Lehúede C, Dupuy F, Rabinovitch R, et al. Metabolic plasticity as a determinant of tumor growth and metastasis. Cancer Res. 2016;76:5201–5208.
   PubMed Web of Science ®Google Scholar
• Dupuy F, Tabariès S, Andrzejewski S, et al. PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab. 2015;22:577–589.
   PubMed Web of Science ®Google Scholar
• Navale AM, Paranjape AN. Glucose transporters: physiological and pathological roles. Biophys Rev. 2016;8:5–9.
   PubMedGoogle Scholar
• Wang J, Ye C, Chen C, et al. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:16875–16886.
   PubMedGoogle Scholar
• Shibuya K, Okada M, Suzuki S, et al. Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells [Internet]. Oncotarget. 2015;6:651–661.
   Google Scholar
• Massihnia D, Avan A, Funel N, et al. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. J Hematol Oncol. 2017;10:9.
   PubMed Web of Science ®Google Scholar
• Liberti MV, Locasale JW. The Warburg Effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211–218.
   PubMed Web of Science ®Google Scholar
• Akram M. Mini-review on glycolysis and cancer. J Cancer Educ. 2013;28:454–457.
   PubMed Web of Science ®Google Scholar
• Bhardwaj V, Rizvi N, Lai MB, et al. Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics. Anticancer Res. 2010;30:743–749.
   PubMed Web of Science ®Google Scholar
• Penny HL, Sieow JL, Adriani G, et al. Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. Oncoimmunology. 2016;5(8):e1191731.
   PubMed Web of Science ®Google Scholar
• Raez LE, Papadopoulos K, Ricart AD, et al. A phase i dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71:523–530.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol (Madr). 2015;54:961–970.
   PubMed Web of Science ®Google Scholar
• Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010;107:2037–2042.
   PubMed Web of Science ®Google Scholar
• Rajeshkumar NV, Dutta P, Yabuuchi S, et al. Therapeutic targeting of the warburg effect in pancreatic cancer relies on an absence of p53 function. Cancer Res. 2015;75:3355–3364.
   PubMed Web of Science ®Google Scholar
• Rani R, Granchi C. Bioactive heterocycles containing endocyclic N-hydroxy groups. Eur J Med Chem. 2015;97:505–524.
   PubMed Web of Science ®Google Scholar
• Maftouh M, Avan A, Sciarrillo R, et al. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br J Cancer. 2014;110:172–182.
   PubMed Web of Science ®Google Scholar
• Calvaresi EC, Granchi C, Tuccinardi T, et al. Dual targeting of the warburg effect with a glucose-conjugated lactate dehydrogenase inhibitor. ChemBioChem. 2013;14:2263–2267.
   PubMed Web of Science ®Google Scholar
• Lee HY, Parkinson EI, Granchi C, et al. Reactive oxygen species synergize to potently and selectively induce cancer cell death. ACS Chem Biol. 2017;12:1416–1424.
   PubMed Web of Science ®Google Scholar
• El Hassouni B, Sciarrillo R, Mantini G, et al. PO-042 targeting hypoxic pancreatic cancer cells with glucose conjugated lactate dehydrogenase inhibitor nhi-glc-2. ESMO. 2018;3(Suppl 2):3082.
   Google Scholar
• Di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology. 2013;144:1220–1229.
   PubMed Web of Science ®Google Scholar
• Pant S, Hubbard J, Martinelli E, et al. Clinical update on K-Ras targeted therapy in gastrointestinal cancers. Crit Rev Oncol Hematol. 2018;130:78–91.
   PubMed Web of Science ®Google Scholar
• Lito P, Solomon M, Li L-S, et al. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2014;351:604–608.
   Web of Science ®Google Scholar
• Bryant KL, Mancias JD, Kimmelman AC, et al. Feeding pancreatic cancer proliferation [Internet]. Trends Biochem Sci. 2014;39:91–100.
   PubMed Web of Science ®Google Scholar
• Cohen R, Neuzillet C, Tijeras-Raballand A, et al. Targeting cancer cell metabolism in pancreatic adenocarcinoma. Oncotarget. 2015;6:16832–16847.
   PubMedGoogle Scholar
• Kimmelman AC. Metabolic dependencies in RAS-driven cancers. Clin Cancer Res. 2015;21:1828–1834.
   PubMed Web of Science ®Google Scholar
• White E. Exploiting the bad eating habits of Ras-driven cancers. Genes Dev. 2013;27:2065–2071. Cold Spring Harbor Laboratory Press.
   Web of Science ®Google Scholar
• Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656–670.
   PubMed Web of Science ®Google Scholar
• Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24:213–228.
   PubMed Web of Science ®Google Scholar
• Xie H, Hanai JI, Ren JG, et al. Targeting lactate dehydrogenase-A inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab. 2014;19:795–809.
   PubMed Web of Science ®Google Scholar
• Detassis S, Grasso M, Del Vescovo V, et al. microRNAs make the call in cancer personalized medicine. Front Cell Dev Biol. 2017;5.
   PubMed Web of Science ®Google Scholar
• Marrugo-Ramírez J, Mir M, Samitier J. Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Multidisciplinary Digital Publishing Institute (MDPI) [ Internet]. Int J Mol Sci. 2018;19:1.
   PubMed Web of Science ®Google Scholar
• Janku F. Tumor heterogeneity in the clinic: is it a real problem? [ Internet]. Ther Adv Med Oncol. 2014;6:43–51. SAGE Publications.
   Web of Science ®Google Scholar
• Ponti G, Manfredini M, Tomasi A. Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology. Crit Rev Oncol Hematol. 2019;141:36–42.
   PubMed Web of Science ®Google Scholar
• Lan F, Yu H, Hu M, et al. MiR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met. J Neurochem. 2015;135:274–286.
   PubMed Web of Science ®Google Scholar
• Liu M, Gao J, Huang Q, et al. Downregulating microRNA-144 mediates a metabolic shift in lung cancer cells by regulating GLUT1 expression. Oncol Lett. 2016;11:3772–3776.
   PubMed Web of Science ®Google Scholar
• Jin LH, Wei C. Role of microRNAs in the Warburg effect and mitochondrial metabolism in cancer. Asian Pacific J Cancer Prev. 2014;15:7015–7019. Asian Pacific Organization for Cancer Prevention.
   Google Scholar
• Wang J, Wang H, Liu A, et al. Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer. Oncotarget. 2015;6:19456–19468.
   PubMedGoogle Scholar
• Xiao X, Huang X, Ye F, et al. The MIR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer. Sci Rep. 2016;6:21735.
   PubMed Web of Science ®Google Scholar
• Ping W, Senyan H, Li G, et al. Increased lactate in gastric cancer tumor-infiltrating lymphocytes is related to impaired T cell function due to miR-34a deregulated lactate dehydrogenase A. Cell Physiol Biochem. 2018;49:828–836.
   PubMedGoogle Scholar
• Li X, Lu P, Li B, et al. Sensitization of hepatocellular carcinoma cells to irradiation by MIR-34a through targeting lactate dehydrogenase-A. Mol Med Rep. 2016;13:3661–3667.
   PubMed Web of Science ®Google Scholar
• Li L, Kang L, Zhao W, et al. miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect. Cancer Lett. 2017;400:89–98.
   PubMed Web of Science ®Google Scholar
• Hua S, Liu C, Liu L, et al. miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA. Biochem Biophys Res Commun. 2018;496:947–954.
   PubMed Web of Science ®Google Scholar
• He Y, Chen X, Yu Y, et al. LDHA is a direct target of miR-30d-5p and contributes to aggressive progression of gallbladder carcinoma. Mol Carcinog. 2018;57:772–783.
   PubMed Web of Science ®Google Scholar
• Chen H, Gao S, Cheng C. MiR-323a-3p suppressed the glycolysis of osteosarcoma via targeting LDHA. Hum Cell. 2018;31:300–309.
   PubMed Web of Science ®Google Scholar
• Zhou S, Min Z, Sun K, et al. miR-199a-3p/Sp1/LDHA axis controls aerobic glycolysis in testicular tumor cells. Int J Mol Med. 2018;42:1786–1798.
   PubMed Web of Science ®Google Scholar
• Li L, Liu H, Du L, et al. MiR-449a suppresses LDHA-mediated glycolysis to enhance the sensitivity of non-small cell lung cancer cells to ionizing radiation. Oncol Res. 2018;26:547–556.
   PubMed Web of Science ®Google Scholar
• Li X, Zhao H, Zhou X, et al. Inhibition of lactate dehydrogenase A by microRNA.34a resensitizes colon cancer cells to 5.fluorouracil. Mol Med Rep. 2015;11:577–582.
   PubMed Web of Science ®Google Scholar